Business Context and Reporting Period
This Form 8-K filing by Histogenics Corporation (not Ocugen, Inc.) covers events occurring on March 14, 2019, and reported on March 15, 2019. The Company is an emerging growth company engaged in a continuing strategic alternative review process. On March 14, 2019, the Board of Directors approved a significant restructuring plan involving drastic headcount reductions to conserve cash and reduce operating costs.
Key Financial Metrics and Restructuring Costs
The filing does not provide current revenue, profit, cash flow, or margin data. The primary financial disclosure relates to the anticipated costs of the restructuring plan.
- Estimated Restructuring Charge: Approximately $2.2 million for severance and related expenses, expected to be recorded by the end of the first quarter of 2019.
- CEO Severance (Adam Gridley): $478,065 lump sum cash payment plus $191,200 retention bonus.
- COO Severance (Stephen Kennedy): $293,906 lump sum cash payment plus $156,750 retention bonus.
- Additional Costs: The Company may incur additional costs not currently contemplated due to events associated with the workforce reduction.
Material Changes Versus Prior Period
The most significant change is the reduction of the workforce to all but one employee. This includes the termination of employment for the Chief Executive Officer (Adam Gridley) and Chief Operating Officer (Stephen Kennedy), effective March 22, 2019. While their employment terminates, both executives will transition to consulting roles to manage the strategic alternative review process through at least June 30, 2019. Mr. Gridley will retain statutory titles of president, treasurer, and secretary and remain a director.
Outlook, Risks, and Management Commentary
Management is evaluating strategic alternatives, which may include the sale of the Company or its assets, or a liquidating distribution to stockholders. The filing highlights substantial risks regarding the Company's ability to pay creditors, successfully complete an orderly wind-up of operations, or liquidate assets outside of a court-supervised proceeding. There is no assurance that the restructuring plan will be completed as anticipated or that the Company will avoid bankruptcy proceedings.
Investor Verification Checklist
- Verify the exact number of remaining employees and the specific roles retained post-restructuring.
- Confirm the final amount of the one-time restructuring charge in the upcoming Form 10-Q for the period ending March 31, 2019.
- Review the full text of the Separation Agreements for Adam Gridley and Stephen Kennedy, which are expected to be filed as exhibits to the Form 10-Q.
- Assess the Company's current cash position and liquidity to determine if it can sustain operations while the strategic review is conducted.
- Monitor for any announcements regarding the completion of a sale, merger, or liquidation plan.